Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO
Titel:
Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO
Auteur:
Cremolini, C. Antoniotti, C. Lonardi, S. Bergamo, F. Cortesi, E. Tomasello, G. Moretto, R. Ronzoni, M. Racca, P. Loupakis, F. Zaniboni, A. Tonini, G. Buonadonna, A. Marmorino, F. Allegrini, G. Granetto, C. Masi, G. Zagonel, V. Sensi, E. Fontanini, G. Boni, L. Falcone, A.